Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform

Gothenburg, July 11, 2023 – Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company’s commercially available platform iTANK^TM, today announced that it has received a Communication under Rule 71(3) EPC (“Notice of Allowance”) from the European Patent Office in its European patent application relating to the use of the iTANK^TM technology in CAR T-cell therapies.

The Communication means that the European Patent Office intends to grant the European patent application after the completion of certain formal steps. Once granted, the patent can be kept in force until 2036.

“We are very pleased to receive a Notice of Allowance in Europe for this important patent application as it adds significant value to our patent portfolio and strengthens the protection around one of our key assets, says Jamal El-Mosleh, CEO of Elicera Therapeutics.